Copyright Reports & Markets. All rights reserved.

Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Sildenafil
      • 1.4.3 Tadalafil
      • 1.4.4 Avanafil
      • 1.4.5 Vardenafil
    • 1.5 Market by Application
      • 1.5.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Application (2019-2025)
      • 1.5.2 Hospital
      • 1.5.3 Retail Pharmacy
      • 1.5.4 Online Pharmacies
      • 1.5.5 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size
    • 2.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Growth Trends by Regions
      • 2.2.1 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Regions (2019-2025)
      • 2.2.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by by Players
      • 3.1.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by by Players (2014-2019)
      • 3.1.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Concentration Ratio (CR5 and HHI)
    • 3.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players Head office and Area Served
    • 3.3 Key Players Phosphodiesterase Type 5 (PDE5) Inhibitor Product/Solution/Service
    • 3.4 Date of Enter into Phosphodiesterase Type 5 (PDE5) Inhibitor Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type (2014-2019)
    • 4.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application (2014-2019)

    5 North America

    • 5.1 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2014-2019)
    • 5.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players in North America
    • 5.3 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type
    • 5.4 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application

    6 Europe

    • 6.1 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2014-2019)
    • 6.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players in Europe
    • 6.3 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type
    • 6.4 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application

    7 China

    • 7.1 China Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2014-2019)
    • 7.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players in China
    • 7.3 China Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type
    • 7.4 China Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application

    8 Japan

    • 8.1 Japan Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2014-2019)
    • 8.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players in Japan
    • 8.3 Japan Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type
    • 8.4 Japan Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2014-2019)
    • 9.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players in Southeast Asia
    • 9.3 Southeast Asia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type
    • 9.4 Southeast Asia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application

    10 India

    • 10.1 India Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2014-2019)
    • 10.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players in India
    • 10.3 India Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type
    • 10.4 India Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size (2014-2019)
    • 11.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Key Players in Central & South America
    • 11.3 Central & South America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type
    • 11.4 Central & South America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application

    12 International Players Profiles

    • 12.1 Eli Lilly
      • 12.1.1 Eli Lilly Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
      • 12.1.4 Eli Lilly Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2014-2019))
      • 12.1.5 Eli Lilly Recent Development
    • 12.2 Pfizer
      • 12.2.1 Pfizer Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
      • 12.2.4 Pfizer Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2014-2019)
      • 12.2.5 Pfizer Recent Development
    • 12.3 Bayer
      • 12.3.1 Bayer Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
      • 12.3.4 Bayer Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2014-2019)
      • 12.3.5 Bayer Recent Development
    • 12.4 Novartis AG
      • 12.4.1 Novartis AG Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
      • 12.4.4 Novartis AG Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2014-2019)
      • 12.4.5 Novartis AG Recent Development
    • 12.5 Merck
      • 12.5.1 Merck Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
      • 12.5.4 Merck Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2014-2019)
      • 12.5.5 Merck Recent Development
    • 12.6 GlaxoSmithKline plc
      • 12.6.1 GlaxoSmithKline plc Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
      • 12.6.4 GlaxoSmithKline plc Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2014-2019)
      • 12.6.5 GlaxoSmithKline plc Recent Development
    • 12.7 Roche
      • 12.7.1 Roche Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
      • 12.7.4 Roche Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2014-2019)
      • 12.7.5 Roche Recent Development
    • 12.8 AstraZeneca
      • 12.8.1 AstraZeneca Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
      • 12.8.4 AstraZeneca Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2014-2019)
      • 12.8.5 AstraZeneca Recent Development
    • 12.9 BaiYunShan General Factory
      • 12.9.1 BaiYunShan General Factory Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
      • 12.9.4 BaiYunShan General Factory Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2014-2019)
      • 12.9.5 BaiYunShan General Factory Recent Development
    • 12.10 SK Chemicals
      • 12.10.1 SK Chemicals Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Introduction
      • 12.10.4 SK Chemicals Revenue in Phosphodiesterase Type 5 (PDE5) Inhibitor Business (2014-2019)
      • 12.10.5 SK Chemicals Recent Development
    • 12.11 Teva Pharma
    • 12.12 Dong-A ST
    • 12.13 Metuchen Pharma
    • 12.14 Seoul Pharma
    • 12.15 Vectura Group

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Product (2019-2025)
    • 13.2 Market Size Forecast by Application (2019-2025)
    • 13.3 Market Size Forecast by Regions
    • 13.4 North America
    • 13.5 Europe
    • 13.6 China
    • 13.7 Japan
    • 13.8 Southeast Asia
    • 13.9 India
    • 13.10 Central & South America

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 15.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      This report focuses on the global Phosphodiesterase Type 5 (PDE5) Inhibitor status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Phosphodiesterase Type 5 (PDE5) Inhibitor development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

      The key players covered in this study
      Eli Lilly
      Pfizer
      Bayer
      Novartis AG
      Merck
      GlaxoSmithKline plc
      Roche
      AstraZeneca
      BaiYunShan General Factory
      SK Chemicals
      Teva Pharma
      Dong-A ST
      Metuchen Pharma
      Seoul Pharma
      Vectura Group

      Market segment by Type, the product can be split into
      Sildenafil
      Tadalafil
      Avanafil
      Vardenafil

      Market segment by Application, split into
      Hospital
      Retail Pharmacy
      Online Pharmacies
      Other

      Market segment by Regions/Countries, this report covers
      North America
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Phosphodiesterase Type 5 (PDE5) Inhibitor status, future forecast, growth opportunity, key market and key players.
      To present the Phosphodiesterase Type 5 (PDE5) Inhibitor development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Phosphodiesterase Type 5 (PDE5) Inhibitor are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
      Buy now